Related Experiment Video
Updated: Jun 4, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms
Daniele Canale1, Mariliza V Rodrigues, Daniele N Ferreira
1Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
Abstract:
Suppression of the renin-angiotensin system (RAS) during murine lactation causes progressive renal injury, indicating a physiological action of angiotensin II on nephrogenesis. The nuclear factor NF-κB system is one of the main intracellular mediators of angiotensin II. We investigated whether inhibition of this system with pyrrolidine dithiocarbamate (PDTC) during rat nephrogenesis would lead to similar hypertension and renal injury as observed with RAS suppressors. Immediately after delivery, 32 Munich-Wistar dams, each nursing 6 male pups, were divided into 2 groups: C, untreated, and PDTC, receiving PDTC, 280 mg kg(-1) day(-1) orally, during 21 days. After weaning, the offspring were followed until 10 months of age without treatment. Adult rats that received neonatal PDTC exhibited stable hypertension and myocardial injury, without albuminuria. To gain additional insight into this process, the renal expression of RAS components and sodium transporters were determined by quantitative real-time PCR (qRT-PCR) at 3 and 10 months of life. Renal renin and angiotensinogen were upregulated at 3 and downregulated at 10 months of age, suggesting a role for early local RAS activation. Likewise, there was early upregulation of the proximal sodium/glucose and sodium/bicarbonate transporters, which abated later in life, suggesting that additional factors sustained hypertension in the long run. The conclusions drawn from the findings were as follows: (1) an intact NF-κB system during nephrogenesis may be essential to normal renal and cardiovascular function in adult life; (2) neonatal PDTC represents a new model of hypertension, lacking overt structural injury or functional impairment of the kidneys; and (3) hypertension in this model seems associated with early temporary activation of renal RAS and sodium transporters.
Insights
Inhibition of the nuclear factor NF-κB system during rat nephrogenesis leads to sustained hypertension and myocardial injury in adulthood. This suggests the NF-κB system is crucial for normal cardiovascular and renal function.
Area of Science:
- Cardiovascular Physiology
- Renal Physiology
- Developmental Biology
Background:
- Renin-angiotensin system (RAS) suppression during lactation causes renal injury, implying angiotensin II's role in nephrogenesis.
- The nuclear factor NF-κB system is a key intracellular mediator of angiotensin II actions.
Purpose of the Study:
- To investigate if inhibiting the NF-κB system during rat nephrogenesis causes hypertension and renal injury.
- To establish a new model for studying hypertension development.
Main Methods:
- Neonatal Sprague-Dawley rats were treated with pyrrolidine dithiocarbamate (PDTC) or left untreated during lactation.
- Offspring were monitored for hypertension, myocardial injury, and albuminuria until 10 months of age.
- Renal expression of RAS components and sodium transporters was analyzed using qRT-PCR.
Main Results:
- Neonatal PDTC administration resulted in stable hypertension and myocardial injury in adult rats, without albuminuria.
- Early upregulation of renal renin, angiotensinogen, and sodium transporters was observed, followed by downregulation.
- Hypertension persisted despite the normalization of RAS components and transporters, suggesting long-term contributing factors.
Conclusions:
- An intact NF-κB system during nephrogenesis is essential for normal adult renal and cardiovascular function.
- Neonatal PDTC treatment provides a novel model of hypertension without overt kidney damage.
- The hypertension observed is linked to early, transient activation of the renal RAS and sodium transporters.

